surgery setting in hospital
Surgery setting in hospital (symbolic photo)

Image source: Shutterstock/DeReGe

News • Promising material

Organ transplantation: polymer coating reduces rejection rate

Researchers have found a way to reduce organ rejection following a transplant by using a special polymer to coat blood vessels on the organ to be transplanted.

The polymer, developed by Prof. Dr. Jayachandran Kizhakkedathu and his team at the Centre for Blood Research and Life Sciences Institute at the University of British Columbia (UBC), substantially diminished rejection of transplants in mice when tested by collaborators at Simon Fraser University (SFU) and Northwestern University. “We’re hopeful that this breakthrough will one day improve quality of life for transplant patients and improve the lifespan of transplanted organs,” said Dr. Kizhakkedathu. The findings were published in Nature Biomedical Engineering.

portrait of Jayachandran Kizhakkedathu
Dr. Jayachandran Kizhakkedathu
Source: UBC

The discovery has the potential to eliminate the need for drugs—typically with serious side effects—on which transplant recipients rely to prevent their immune systems from attacking a new organ as a foreign object. Dr. Kizhakkedathu explained how that problem arises: “Blood vessels in our organs are protected with a coating of special types of sugars that suppress the immune system’s reaction, but in the process of procuring organs for transplantation, these sugars are damaged and no longer able to transmit their message.”

Dr. Kizhakkedathu’s team synthesized a polymer to mimic these sugars and developed a chemical process for applying it to the blood vessels. He worked with UBC chemistry professor Dr. Stephen Withers and the study’s co-lead authors, PhD candidate Daniel Luo and recent chemistry PhD Dr. Erika Siren.

portrait of erika siren
Dr. Erika Siren
Source: UBC

Dr. Siren’s thinking on cell-surface engineering had been inspired by a visit to a BC Transplant facility. “I remember seeing an organ sitting in a solution and thinking, ‘Here’s a perfect window to engineer something right,'” Dr. Siren recalled. “There aren’t a lot of situations where you’ve got this beautiful four-hour window where the organ is outside the body, and you can directly engineer it for therapeutic benefit.”

The work of Simon Fraser University’s Dr. Jonathan Choy and Winnie Enns confirmed that a mouse artery, coated in this way and then transplanted, would exhibit strong, long-term resistance to inflammation and rejection. Dr. Caigan Du of UBC and Dr. Jenny Zhang of Northwestern University then got similar results from a kidney transplant between mice. Dr. Megan Levings of UBC and the BC Children’s Hospital Research Institute firmed up the findings using new-generation immune cells. “We were amazed by the ability of this new technology to prevent rejection in our studies,” said Dr. Choy, professor of molecular biology and biochemistry at SFU. “To be honest, the level of protection was unexpected.”

The procedure has been applied only to blood vessels and kidneys in mice so far. Clinical trials in humans could still be several years away. Still, the researchers are optimistic it could work equally well on lungs, hearts and other organs, which would be great news for prospective recipients of donated organs.


Source: University of British Columbia

10.08.2021

Read all latest stories

Related articles

Photo

News • Cardiology research

Are hearts from Covid-19 positive donors safe for transplantation?

Donor hearts from people who were Covid-19-positive appear to be as safe for transplantation as those from people without Covid-19, according to a new short-term analysis.

Photo

News • Organ transplantation

New treatment could improve donor lung availability

Researchers at Lund University in Sweden and Skåne University Hospital have conducted an animal study bringing hope that more donor lungs could be used in the future.

Photo

News • Coronavirus mechanism discovered

Organ-on-a-chip reveals how SARS-CoV-2 invades blood vessels

A research group has revealed that SARS-CoV-2 disrupts the vascular endothelial barrier by suppressing the expression of Claudin-5 (CLDN5) to invade the blood vessels.

Related products

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Canon – Alphenix Core

Single Plane

Canon – Alphenix Core

Canon Medical Systems Europe B.V.
Canon – Alphenix Core+ High Definition Detector

Single Plane

Canon – Alphenix Core+ High Definition Detector

Canon Medical Systems Europe B.V.
Canon – Alphenix Sky

Single Plane

Canon – Alphenix Sky

Canon Medical Systems Europe B.V.
Canon – Alphenix Sky

Single Plane

Canon – Alphenix Sky

Canon Medical Systems Europe B.V.
Canon – Alphenix Sky+

Single Plane

Canon – Alphenix Sky+

Canon Medical Systems Europe B.V.
Subscribe to Newsletter